biomed devic servic
execut plan still earli process
hold pt
bottom line maintain hold rate post result overal result
encourag pocket perform continu apac strength remain
cautiou time acceler top-lin growth unlock sharehold valu
think unchang guidanc appropri conserv
 xfx sale growth commentari season time new product
launch control full commerci releas increasingli weight
second half believ reflect time invest requir
turnaround play stick hold
sum current valuat ep estim surpris
long-term investor start opportunist build posit next six
month particularli given manag provid enough forward inform
start piec togeth mosaic howev messag regard timelin
suppli new product turnaround sale momentum increasingli make
feel like late event maintain hold given expect share
remain range-bound upsid top-lin growth target look
challeng supply/manufactur issu weigh margin next
top line post revenu compar cg/street estim
apac continu strong momentum xfx growth
continu benefit weight legaci zimmer product less
affect suppli issu
manufactur qualiti call manag reiter confid
progress make remedi effort state remain
track two-year turnaround plan set compani resum market
rate top-lin growth oper focu begin shift simpli
stabil suppli drive effici improv cost structur addit
manag note dramat cultur chang insid compani
continu optim talent structur said guidanc
unchang posit develop oper side alreadi
anticip point continu think qualiti issu resolv
remain cautiou regard near-term leverag upsid
pipelin updat manag reiter expect pipelin product play
import part compani return sustain revenu earn growth
note zimmer continu highlight persona trabecular metal tibia allow
zimmer offer full cementless knee recent fda approv rosa
robot system note compani robot platform across
brain spine knee applic manag detail initi commerci plan
focu sell rosa platinum account market-
share high-volum practic continu view pipelin posit howev
expect take least product materi
impact top-lin growth
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
zimmer report sale slightli estim
street revenu support continu strength
asia pacif region expect off-set weak
emea expect addit qualiti remedi effort
manufacturing/ suppli issu continu impact margin due higher product
cost includ dual sourc inventori outsid vendor invest
 adjust gross margin came y/i pro forma
oper margin y/i second consecut
quarter zimmer report adjust ep compar estim
street
figur result vs estim consensu
guidanc unchang remind come manag
guid report sale growth rang compar
current cg/consensu estim rang includ expect
neg bp fx impact impli improv organ growth
 y/i pro forma ep expect guid rang
compar cg/consensu estim adjust oper
margin guid rang line estim
compani adjust tax rate expect line
estim free cash flow guid rang in-lin
estim
hold unchang target price april
biomed devic servic
overal performanceactualcg estimatebeat/miss beat/miss consensusbeat/missnet good gross pro-forma oper net revenu productactualcg estimatebeat/miss beat/miss growthnet revenu geographyactualcg estimatebeat/miss beat/miss growthnet number us million zimmer biomet hold
chang estim
made follow chang estim
figur summari chang estim
broad large-cap med-tech group current trade mean price-to-earnings multipl
valu zimmer discount large-cap med-tech group given
uncertainti surround remedi suppli issu impact revenu
margin sum adjust pt base price-to-earnings multipl
appli pro-forma ep
hold unchang target price april
biomed devic servic
except ep newold newold newold revenu gross operatin ebitda net zimmer biomet hold
figur matrix discount rate impli share price target
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
hold unchang target price april
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price april
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep ep chg share gener oper rate adjust growth ep ex growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
hold unchang target price april
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
